Purpose: The prospective, multicenter LOCATE ( 18 F Fluciclovine [FACBC] PET/ CT in Patients with Rising PSA after Initial Prostate Cancer Treatment) trial assessed the impact of positron emission tomography/computerized tomography with 18 F-fluciclovine on treatment plans in patients with biochemical recurrence of prostate cancer after primary therapy with curative intent. Materials and Methods: Men who had undergone curative intent treatment of histologically confirmed prostate cancer but who were suspected to have recurrence based on rising prostate specific antigen levels were enrolled prospectively. Each man had negative or equivocal findings on standard of care imaging. 18 F-fluciclovine positron emission tomography/computerized tomography was performed according to standardized protocols. Treating physicians completed a questionnaire regarding the patient treatment plan before and after scanning, recording changes to the treatment modality (eg salvage radiotherapy to systemic androgen deprivation therapy) as major and changes in a modality (eg modified radiotherapy fields) as other. Results: Between June 2016 and May 2017, 213 evaluable patients with a median age of 67 years and median prostate specific antigen 1.00 ng/ml were enrolled in study.
RELAPSE remains common despite advances in primary treatment and improved overall survival of prostate cancer with BCR developing in 20% to 40% of patients.
1e4 Although a significant proportion of men with BCR undergo salvage therapy, localization of recurrence with standard imaging remains challenging, especially when PSA levels are low. 5, 6 Consequently local therapy guided by nomogram based probabilities is often selected rather than anatomical localization of recurrent disease. 7 An imaging modality providing anatomical localization of recurrence in patients with low PSA would facilitate treatment planning, leading to a better chance of cure when tumors are small and amenable to localized therapy, avoiding futile salvage therapy and informing decisions to delay ADT with its associated morbidity. 8, 9 Currently PET has limited usefulness in prostate cancer. Although widely available, FDG ( 18 Ffluorodeoxyglucose) PET/CT is not routinely used for prostate cancer imaging due to low uptake except in castrate resistant disease.
11 C-choline is FDA (Food and Drug Administration) approved and some 18 F-choline analogues are approved in some European countries. 11 C-choline yields slightly better disease staging than FDG but remains suboptimal, particularly for identifying extraprostatic lesions, with limited accuracy in patients with low PSA and slow kinetics. 5,6,10e13 Moreover, 11 C based PET radiotracers have a 20-minute half-life, making them unsuitable for use at centers without cyclotrons on site. PSMA based radiotracers such as 68 Ga-PSMA-11 are in development and show promising results in recurrent prostate cancer cases with meta-analysis data showing a pooled, subject level detection rate of 76%. 14 The synthetic amino acid radiotracer 18 Ffluciclovine is approved by the FDA and the EU (European Commission) to detect prostate cancer in patients with elevated PSA following prior treatment. Approval was based on encouraging diagnostic performance and histologically confirmed data on patients with BCR showing 68% subject level detection, 62% positive predictive value (greater than 90% for extraprostatic disease) and 70% specificity. 15 A recent update to the NCCN Guidelines Ò recommends that 18 F-fluciclovine PET/ CT or PET/MRI be considered in the workup of patients with prostate cancer recurrence or progression. 16 Given the established performance of 18 Ffluciclovine PET/CT and its approved United States indication to document PSA recurrence, we present results from the multicenter LOCATE trial. The trial was done to evaluate the impact of 18 F-fluciclovine PET/CT on the planned treatment of patients with prostate cancer BCR after curative intent primary therapy and negative/equivocal standard of care imaging. Ongoing data analysis will provide secondary information on the correlation with biopsy, when performed, and clinical followup.
METHODS
Design LOCATE (ClinicalTrials.gov NCT02680041) was an open label, multicenter, interventional, single group assignment phase 4 trial across 15 sites in the United States. The primary objective was to measure the proportion of patients with suspected prostate cancer BCR after primary therapy with curative intent in whom the planned treatment was altered after 18 F-fluciclovine PET/CT. Secondary end points included analysis of patients whose actual treatment deviated from the revised plan. Groups at participating institutions obtained Institutional Review Board approval before accrual and all patients provided written informed consent (supplementary table, http://jurology.com/).
Patients
Men 18 years old or older with histologically confirmed prostate cancer who were considered for salvage therapy because of rising PSA were eligible if they had negative or equivocal findings on 2015 or 2016 recommended United States standard of care imaging (abdominopelvic CT or MRI and bone scintigraphy) for disease restaging in the preceding 60 days. BCR was diagnosed after prostatectomy with or without adjuvant radiotherapy as detectable or rising PSA 0.2 ng/ml or greater with a second confirmatory level of 0.2 ng/ml or greater. In patients who had undergone radiotherapy or brachytherapy BCR was diagnosed by a PSA increase of 2.0 ng/ml or greater above the nadir. 17 Study exclusion criteria were ongoing treatment with any prostate cancer systemic therapy, ADT 3 months or less before screening, bilateral orchiectomy and intolerance of 18 F-fluciclovine. Nonsurgical local treatment must have occurred 1 year or more before enrollment and brachytherapy must have occurred 2 or more years previously.
Protocol
Baseline screening was performed during the first visit of each patient ( fig. 1) . The physician completed a questionnaire to document the patient treatment plan before and again 2 to 22 days after 18 F-fluciclovine PET/CT to document changes resulting from the scan (supplementary fig. 1 , http://jurology.com/). A change of management involving a new treatment modality (eg salvage radiotherapy to systemic therapy) was classified as major while any change in a modality (eg modified radiotherapy fields) was classified as other. At 26 AE 4 weeks after PET/CT the actual treatment was recorded to document changes from the revised plan. Readers were trained to interpret 18 F-fluciclovine PET/ CT images according to 2014 consensus guidelines (supplementary Appendix, http://jurology.com/). 19 Anatomical locations were categorized as positive or negative for uptake when determining the positivity rate at the subject level for the prostate/prostate bed and for extraprostatic regions (lymph nodes, bone or soft tissue).
Statistics
The sample size calculation was based on binding the width of the 95% CI within 0.20 using the ClopperPearson exact method in PASS, version 12 (NCSS, Kaysville, Utah), the worldwide leading software to determine sample size. We assumed that approximately 30% of positive scans would change the intended management plan. 20 Thus, 89 patients with positive 18 Ffluciclovine PET/CT findings were needed to assess the primary end point. The prevalence of positive 18 Ffluciclovine PET/CT was assumed to be about 40% and, thus, we expected to enroll 223 patients. Because of the random nature of the number of patients meeting clinical criteria in prospective studies, we applied a sample size correction. 21 By adding 25 extra patients we could be 90% certain to yield the required number of patients who met the criteria. Assuming a 15% potential data loss, a total sample of 292 patients was estimated.
RESULTS

Patients
Because of a higher positivity rate and a lower data loss than anticipated, recruitment was terminated following the enrollment of 221 patients. Two patients subsequently withdrew consent and screening failed in 6. Thus, 213 evaluable patients were scanned between June 2016 and May 2017 (supplementary fig. 2 , http://jurology.com/). Patients were a median 54 months after the initial diagnosis, median age was 67.0 years and median prescan PSA was 1.00 ng/ml (see table) .
Imaging Figure 2 shows representative images. Conventional imaging revealed at least 1 equivocal finding in 34 patients (16%) while the remainder had negative results. The most recent result in each patient occurred a median of 30 days (range 2 to 124) before scanning. Within the preceding 60 days bone scan, CT or MRI was negative/equivocal in 175, 133 and 38 patients, respectively. Of the negative/equivocal bone scans the subsequent 18 F-fluciclovine PET/CT detected bone lesions in 9.7%. 18 F-fluciclovine PET/CT detected prostate/bed or pelvic lesions in 52% and 47% of those with negative/equivocal pelvic CT and MRI, respectively. Overall 18 F-fluciclovine avid lesions were detected in 122 of 213 patients (57%) ( fig. 3, A) . The detection rate was 30% in the prostate/prostate bed and 38% outside the prostate, including 29% in lymph nodes, 2.3% in soft tissue and 11% in bone.
Detection Rate vs Prostate Specific Antigen
The 18 F-fluciclovine PET/CT detection rate was broadly proportional to prescan PSA ( fig. 3, B) . Lesions were detected in 84 of 106 patients (79%) with PSA greater than 1.0 ng/ml and in 65 of 77 (84%) with PSA greater than 2.0 ng/ml.
Among those with the lowest PSA (0 to 0.5 ng/ml) the patient level detection rate was 31%, including 16% for the prostate/prostate bed and 17% for Figure 1 . LOCATE study design. AE, adverse event. Asterisk indicates that biopsy may be done after scan when clinically indicated. extraprostatic sites. In patients with PSA greater than 0.5 to 1.0 ng/ml positivity was 50%, which rose to 66% in those with PSA greater than 1.0 to 2.0 ng/ ml. For extrapelvic lymph nodes (retroperitoneal and other) positivity ranged from 3.7% at PSA 0.5 ng/ml or less to 42% at PSA greater than 10 ng/ml. Skeletal positivity was 7.4% at PSA 0.5 ng/ml or less and 14% at PSA greater than 2 ng/ml.
Therapeutic Management Plans
Intended. The most common prescan management plan was radiotherapy performed in 128 cases (60%). In 52 of these patients (41%) adjuvant ADT was also planned and in a further 60 (28%) ADT monotherapy was planned ( fig. 4, A) . The most frequent change was to withhold planned salvage or noncurative systemic therapy in favor of watchful waiting. This applied to 15% of patients and accounted for 32 of all 126 management changes (25%), including 11 from intended ADT, 16 from radiotherapy (4 with adjuvant ADT), 2 from cryotherapy (1 with adjuvant ADT), 2 from prostatectomy and 1 from lymphadenectomy. The decision to revise plans to watchful waiting was informed by negative 18 F-fluciclovine PET/CT in 21 patients (66%).
2) At a comparable frequency planned ADT was revised to curative intent salvage therapy (radiotherapy, brachytherapy or cryotherapy) in 30 of 126 patients (24%). PET/CT was positive in 28 of these patients (93%). Of 60 patients whose original plan was ADT monotherapy 45 (75%) had treatment changed after PET/CT. There were major changes in 41 of the 45 cases (91%), most commonly a change to salvage radiotherapy in 15, including 9 with adjuvant ADT.
3) Of all 126 changes 11 (9%) were from salvage therapy with or without ADT to systemic monotherapy with ADT. Eight of these patients (73%) had positive 18 F-fluciclovine PET/CT, often with distant metastases, eg to retroperitoneal lymph nodes (5 patients) or distant soft tissue and parenchymal metastasis (bowel in 1 patient). Of the 128 men whose intended plan was salvage radiotherapy with or without ADT 65 (51%) had the treatment changed after the scan and 44 were major changes, including 19 changes to ADT (ADT plus radiotherapy in 13 and ADT monotherapy in 6).
4) The majority of management changes classified as other were modifications to radiotherapy fields. These modifications accounted for 20 of all 126 management changes (16%). They were informed by positive PET/CT in 85% of cases, most commonly when a positive finding was identified that was not targeted by the original field.
Actual. Six-month followup data documenting the actual treatment that patients received were available on 211 of the 213 patients (99%). While treatment in 132 patients (63%) was concurrent with the post-PET/CT plans, a clinically important difference was found in 79 (37%). 18 F-fluciclovine PET/CT was negative in 42% of these patients.
The documented changes comprised a delay to planned treatment in 3.8% of patients, revision following further imaging, tests or specialist opinion in 15%, an altered regimen of planned treatment in 5.1%, addition of a new therapy in 13%, receipt of only 1 of 2 planned elements given to date in 7.6%, a change to watchful waiting based on patient preference in 44% or another change in 11%. Of the 35 patients who elected watchful waiting 57% had a negative 18 F-fluciclovine PET/CT. Importantly only 4 of the 79 modifications (5.1%) from the post-PET plan restored treatment back to the prePET plan. Of the 79 patients whose actual treatment changed 46% had no prePET to post-PET change.
DISCUSSION
To determine whether disease localization with 18 Ffluciclovine PET/CT would influence patient treatment we enrolled 213 patients at a total of 15 centers in the United States. Lesions were detected in 57% of patients and in 59% the management plan was changed after the scan. Approximately threequarters of the changes were major changes from one modality to another.
Our findings are similar to those recently presented from the smaller United Kingdom based FALCON (Fluciclovine [
18 F] PET/CT in Biochemical Recurrence of Prostate Cancer) trial. 22 FALCON data showed that 61% of 85 men with BCR had management plans changed following 18 F-fluciclovine PET/CT and approximately 60% of the changes were major.
Standard imaging for BCR has limited accuracy, particularly in men with low PSA. 5, 6, 16 The current findings confirm and extend previous histologically confirmed findings showing 18 F-fluciclovine detected disease not seen on standard imaging. 15, 23 The usefulness of alternative PET radiotracers to inform disease management decisions 24, 25 is in the same range as we report for 18 F-fluciclovine. A study evaluating the impact of choline PET/CT on the treatment of 33 patients with BCR (median 2 ng/ml PSA, range 0.16 to 79) showed choline uptake in the prostate, prostate fossa and pelvic lymph nodes in 17 and remote disease in 9. 24 However, the cause of BCR was not identified on 7 scans, together leading to modification of treatment plans for 18 patients (55%).
68
Ga-PSMA-11 PET/CT informed major changes to initial management plans in 53% of 126 patients with BCR and minor changes in 6.4%. 25 Patients who initially undergo gland sparing treatments are typically offered salvage focal therapy such as brachytherapy or cryotherapy (with or without ADT). 5, 6, 16 However, the majority of men with BCR who are considered for salvage therapy after curative intent prostatectomy will undergo salvage prostate bed irradiation without prior identification of the actual recurrence site(s). Indeed, in the 77% of men in our cohort who underwent prostatectomy as initial therapy more than half were scheduled to undergo salvage radiotherapy before the results of 18 F-fluciclovine PET/CT were available.
Because of the poor performance of conventional imaging, salvage therapy decisions have traditionally been based on clinical judgment, patient and physician preference, the probability of disease progression and the risk-to-benefit profile of each treatment. 7 The current study demonstrates a role for 18 F-fluciclovine PET/CT in disease staging and management planning. However, additional studies 18 F-fluciclovine imaging detection rate by region (A) and PSA (B). Extraprostatic region consisted of lymph nodes, soft tissues/ parenchyma and bone. Lymph nodes consisted of pelvic and extrapelvic (retroperitoneal and other) nodes with overall 24% and 12% detection rate, respectively. Soft tissue/parenchyma positivity was identified in bowel and lung. Error bars indicate 95% CI.
are needed to assess the impact on patient outcomes as a result of refining management plans to increase the chance of durable progression-free survival or the avoidance of therapy that will ultimately be futile.
We frequently observed the modification of salvage or systemic therapy to watchful waiting in patients with negative PET/CT, suggesting that the patient and the physician were reassured by the absence of visible disease and decided not to intervene but instead to monitor closely. Positive 18 F-fluciclovine PET/CT also led to treatment modification, notably when distant metastases were identified by PET/CT, eg in retroperitoneal lymph nodes or bowel soft tissue, prompting the decision to abandon intended salvage radiotherapy to the prostate bed and/or pelvis. Consequently these men were spared the morbidity of salvage radiotherapy. 26, 27 Similarly, approximately a sixth of patients were spared ADT and its associated morbidity 8,9 after 18 Ffluciclovine PET/CT showed anatomically localized positive lesions which could be better targeted by a salvage modality.
The ability of 18 F-fluciclovine PET/CT to assist radiotherapy planning was reported previously. 20 We frequently observed lesions outside the prescan treatment field in patients scheduled to undergo salvage radiotherapy. In a randomized, prospective trial in 87 subjects with post-prostatectomy BCR initial radiotherapy plans were compiled based on conventional imaging. 20 Of the 87 patients 42 were randomized to undergo additional 18 F-fluciclovine PET/CT. Of the men 81% had positive PET/CT results, leading to revised radiotherapy plans in 41%. In a subanalysis of a cohort of the first enrolled patients in the study 18 F-fluciclovine PET/CT led to the augmentation of planned radiotherapy target volumes for the prostate bed and the lymph nodes in 30 of 41 patients (73%). 28, 29 As a change in management does not necessarily confer improved outcomes, longer term followup ideally via a patient registry is needed to confirm how incorporating 18 F-fluciclovine PET/CT into therapy planning would affect outcomes. Approximately a third of patients at the 6-month followup had a clinically significant modification from the post- 18 F-fluciclovine PET/CT treatment plan. Reassuringly the rate of change was similar among those whose initial treatment plan was changed by 18 Ffluciclovine PET/CT vs those whose initial treatment plan was not changed. Moreover, only 5% of the changes recorded at 6 months restored management to that intended before 18 F-fluciclovine PET/CT. While in the current study we did not routinely confirm imaging results with histological findings, prior histologically confirmed data demonstrate good diagnostic performance of 18 F-fluciclovine PET/CT. 15 However, higher specificity is noted in extraprostatic lesions compared with the treated prostate, perhaps because of overlap between malignancy, benign hyperplasia and prostatitis. 15 
CONCLUSIONS
Localization of recurrent prostate cancer with 18 Ffluciclovine PET/CT had considerable impact on patient treatment with the majority of patients receiving a treatment modality that differed from the prescan management plan. 18 F-fluciclovine PET/CT has the potential to improve management but further investigation is warranted. 
